Business Case for an rTMS Clinic in Canada: A Practical Framework
Can a clinically sound rTMS service succeed if referrals, treatment capacity, or funding pathways are uncertain? A defensible business case for rTMS…
Mastering TMS: The MagVenture Accelerator Training Path for Canadian Clinicians
With rTMS showing remission rates of 30-35% in patients with medically refractory depression, the difference between clinical success and stalled…
Expanding Neuromodulation: Clinical Training Guide
With the Canadian neuromodulation market projected to reach C$296.8 million by 2030, the shift toward non-invasive therapies like rTMS is no longer a…